Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sava

Showing results (1-10 of 194) with videos related to

Pageof 20
Sort By:
EXS|January 1, 1996
Pharmacological aspects and therapeutic applications of lysozymesG Sava
Cancer Chemotherapy and Pharmacology|January 1, 1989
Reduction of B16 melanoma metastases by oral administration of egg-white lysozymeG Sava
In Vivo (Athens, Greece)|February 24, 2001
Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogsG Sava, M Cocchietto
Cancer Chemotherapy and Pharmacology|January 1, 1983
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in miceG Sava, T Giraldi
International Journal of Oncology|July 13, 2000
Ruthenium-based compounds and tumour growth control (review)G Sava, A Bergamo
Anticancer Research|June 16, 1999
Drug control of solid tumour metastases: a critical viewG Sava, A Bergamo
Pharmacology & Toxicology|December 29, 2000
Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in miceM Cocchietto, G Sava
Anticancer Research|January 1, 1981
Selective antimetastatic drugs (review)T Giraldi, G Sava
Dalton Transactions (Cambridge, England : 2003)|March 21, 2007
Ruthenium complexes can target determinants of tumour malignancyA Bergamo, G Sava
Annales De Chirurgie|May 1, 1970
[Clinical study of extensive resections of the small intestine]L F Hollender, G Sava
Pageof 20

Showing results (1-10 of 194) with videos related to

Sort By:
Pageof 20
EXS|January 1, 1996
Pharmacological aspects and therapeutic applications of lysozymesG Sava
Cancer Chemotherapy and Pharmacology|January 1, 1989
Reduction of B16 melanoma metastases by oral administration of egg-white lysozymeG Sava
In Vivo (Athens, Greece)|February 24, 2001
Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogsG Sava, M Cocchietto
Cancer Chemotherapy and Pharmacology|January 1, 1983
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in miceG Sava, T Giraldi
International Journal of Oncology|July 13, 2000
Ruthenium-based compounds and tumour growth control (review)G Sava, A Bergamo
Anticancer Research|June 16, 1999
Drug control of solid tumour metastases: a critical viewG Sava, A Bergamo
Pharmacology & Toxicology|December 29, 2000
Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in miceM Cocchietto, G Sava
Anticancer Research|January 1, 1981
Selective antimetastatic drugs (review)T Giraldi, G Sava
Dalton Transactions (Cambridge, England : 2003)|March 21, 2007
Ruthenium complexes can target determinants of tumour malignancyA Bergamo, G Sava
Annales De Chirurgie|May 1, 1970
[Clinical study of extensive resections of the small intestine]L F Hollender, G Sava
Pageof 20